Team Pinpoints New Targets for Treating Adult Blood Cancer – Technology Networks

We’ve updated our Privacy Policy to make it clearer how we use your personal data.
We use cookies to provide you with a better experience. You can read our Cookie Policy here.
Complete the form below and we will email you a PDF version of “Team Pinpoints New Targets for Treating Adult Blood Cancer With Gene Editing Tech”
Gene editing technology has been used to pinpoint new molecular targets for treating an aggressive form of leukemia in adults.
Hokkaido University scientists have identified new targets for treating an aggressive form of adult leukemia with existing drugs. The findings were published in the journal Blood.

Adult T-cell leukemia/lymphoma (ATLL) is an aggressive form of blood cancer that is linked to a viral infection. Currently available chemotherapies are not particularly effective in treating the disease, which has a long-term survival rate of only 20%. Much research has been done to explore the molecular pathways and gene mutations involved in this cancer, but these vary between patients, making it difficult to develop effective treatments.

Hokkaido University hematologist Masao Nakagawa and colleagues in Japan, the US and France used the CRISPR-Cas9 gene editing technology to inactivate thousands of genes in several ATLL cell lines. Their aim was to pinpoint genes and pathways that could be targeted with drugs to kill ATLL cells. The process led to the identification of 1,278 genes that were essential for the survival and proliferation of ATLL cells. They then narrowed down this number to nine genes for more detailed investigations.

Among these, one gene proved particularly promising as a drug target. The gene CDK6 encodes an enzyme that activates cell proliferation. The scientists found that inactivating the enzyme with a drug currently used to treat breast cancer, called palbociclib, stopped cell division and caused cell death in some, but not all, of the tested ATLL cell lines.

The cell lines that were resistant to the drug had a mutation in a gene called TP53, which under normal circumstances is involved in inhibiting tumor growth and development. These cells died when treated with palbociclib together with an activator of mutant TP53; a drug that is currently used to treat a type of blood cancer called myelodysplastic syndrome.

Importantly, the researchers also found that combining palbociclib with the drug everolimus, which is used to treat kidney and breast cancer, also killed ATLL cells, including those with TP53 mutations. The drug combination also significantly reduced tumor growth and had minimal side effects when tested in mice with grafted ATLL tumors. Everolimus inhibits a protein complex, called mTORC1, which is involved in protein synthesis for cell growth and proliferation.

“Our study reveals CDK6 as an attractive target for treating ATLL,” says Nakagawa. “However, we also discovered that loss of TP53 function in some ATLL cell lines leads to resistance to the CDK6 inhibitor, palbociclib. Given this finding, researchers should consider the status of TP53 in future clinical trials of palbociclib in ATLL.”

Reference: Ishio T, Kumar S, Shimono J, et al. Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma. Blood. 2022;139(10):1541-1556. doi: 10.1182/blood.2021012734

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

source

Share:

More Posts

Market Research

Pulse Surveys

Turn feedback into action

Our survey platform makes it easy to measure and understand feedback so you can drive growth and innovation

Pulse Handshak

Pulse Handshak

Collaborative online survey tool for the market research industry. Remote assisted surveying just like face-to-face interviews. Here interviewers can talk to the respondent over the web-console without the need for any other communication channel and share the same Q're with responses and click actions.

Pulse FE

Pulse FE

Pulse Field Expert or Pulse FE is the main platform for both offline and online survey at softofficepro.com. It is robust and used by hundreds of clients over tens of years with millions of responses. Do it once Q're and deploy on both offline devices (android) and online forms makes it a great cost effective platform for any kind of responses

Pulse Ultimate

Pulse Ultimate

Pulse Ultimate is targeted for tracking studies and retail audits. An offline survey system offering extreme field control including processes like data quality check, back-check, rework, comparison with previous wave data etc. helps to get the best results on a day-to-day basis

Pulse LS

Pulse LS

Use a managed Limesurvey and our expertise for creating complex forms and token based user management. Use optional mailing system to send survey invitation to each participant and track progress of the response status. Industry standard SPSS / R output supported